PPARA and metabolic dysfunction-associated steatotic liver disease: KEGG pathway analysis of differentially expressed genes identified from DhT‐treated mice versus HCD mice revealed the involvement of the PPAR signaling pathway (Figure 7B), aligning with the concept that PPARs are potential therapeutic targets for NAFLD.[31] Next, the expression of three isoforms of PPARs, including PPARα, PPARγ and PPARδ, have been detected both in vitro and in vivo.